149 related articles for article (PubMed ID: 32645997)
1. DrugSniper, a Tool to Exploit Loss-Of-Function Screens, Identifies
Carazo F; Bértolo C; Castilla C; Cendoya X; Campuzano L; Serrano D; Gimeno M; Planes FJ; Pio R; Montuenga LM; Rubio A
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32645997
[TBL] [Abstract][Full Text] [Related]
2. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
[TBL] [Abstract][Full Text] [Related]
3. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536.
Breitenbuecher F; von Pawel J; Sebastian M; Kortsik C; Ting S; Kasper S; Wohlschläger J; Worm K; Morresi-Hauf A; Schad A; Westerwick D; Wehler B; Werner M; Munzert G; Gaschler-Markefski B; Schmid KW; Schuler M
Oncol Res Treat; 2017; 40(7-8):435-439. PubMed ID: 28628916
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancer.
Wildey G; Chen Y; Lent I; Stetson L; Pink J; Barnholtz-Sloan JS; Dowlati A
PLoS One; 2014; 9(9):e106784. PubMed ID: 25198282
[TBL] [Abstract][Full Text] [Related]
7. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract][Full Text] [Related]
8. Identifying Lethal Dependencies with HUGE Predictive Power.
Gimeno M; San José-Enériz E; Rubio A; Garate L; Miranda E; Castilla C; Agirre X; Prosper F; Carazo F
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805023
[TBL] [Abstract][Full Text] [Related]
9. Kinome-wide CRISPR-Cas9 knockout screens revealed PLK1 as a therapeutic target for osteosarcoma.
Wang R; Wang D; Bai X; Guo J; Xia S; Cheng Y; Gu Y; Wang Q; Nie J; Chen D; Liu W; Liang J
Cell Death Discov; 2023 Jul; 9(1):231. PubMed ID: 37419907
[TBL] [Abstract][Full Text] [Related]
10. Polo-Like Kinase 1 phosphorylates and stabilizes KLF4 to promote tumorigenesis in nasopharyngeal carcinoma.
Mai J; Zhong ZY; Guo GF; Chen XX; Xiang YQ; Li X; Zhang HL; Chen YH; Xu XL; Wu RY; Yu Y; Li ZL; Peng XD; Huang Y; Zhou LH; Feng GK; Guo X; Deng R; Zhu XF
Theranostics; 2019; 9(12):3541-3554. PubMed ID: 31281496
[No Abstract] [Full Text] [Related]
11. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
[TBL] [Abstract][Full Text] [Related]
12. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomic Analysis Reveals
Lee Y; Lee CE; Oh S; Kim H; Lee J; Kim SB; Kim HS
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486290
[TBL] [Abstract][Full Text] [Related]
14. Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy.
Patel SR; Das M
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627044
[TBL] [Abstract][Full Text] [Related]
15. A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer.
Li L; Xue W; Shen Z; Liu J; Hu M; Cheng Z; Wang Y; Chen Y; Chang H; Liu Y; Liu B; Zhao J
Mol Ther Oncolytics; 2020 Sep; 18():215-225. PubMed ID: 32728610
[TBL] [Abstract][Full Text] [Related]
16. Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.
Van den Bossche J; Lardon F; Deschoolmeester V; De Pauw I; Vermorken JB; Specenier P; Pauwels P; Peeters M; Wouters A
Med Res Rev; 2016 Jul; 36(4):749-86. PubMed ID: 27140825
[TBL] [Abstract][Full Text] [Related]
17.
Li L; Li W; Chen N; Zhao H; Xu G; Zhao Y; Pan X; Zhang X; Zhou L; Yu D; Li A; Hu JF; Cui J
Clin Cancer Res; 2019 Feb; 25(4):1302-1317. PubMed ID: 30429198
[TBL] [Abstract][Full Text] [Related]
18. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
Strebhardt K; Becker S; Matthess Y
Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
[TBL] [Abstract][Full Text] [Related]
19. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
